Respiratory pathogens and clinical outcomes in children with an asthma exacerbation: A systematic review.

BACKGROUND

In asthmatic children, respiratory pathogens are identified in 60%-80% of asthma exacerbations, contributing to a significant burden of illness. The role of pathogens in the clinical evolution of exacerbations is unknown.

OBJECTIVE

We systematically reviewed the association between the presence of pathogens and clinical outcomes in children with an asthma exacerbation.

METHOD

PubMed, EMBASE, BIOSIS, and the Cochrane Central Register of Controlled Trials were searched up to October 2016 for studies reporting on respiratory pathogen exposure and clinical outcome. The Risk of Bias in Non-Randomized Studies of Interventions tool was used for quality assessment.

RESULTS

Twenty-eight observational studies ( = 4,224 children) reported on 112 different associations between exposure to any pathogen ( = 45), human rhinovirus (HRV; = 34), atypical bacteria ( = 21), specific virus ( = 11), or bacteria ( = 1) and outcomes of exacerbation severity ( = 26), health care use ( = 38), treatment response ( = 19), and morbidity ( = 29). Restricting the analysis only to comparisons with a low to moderate risk of bias, we observed an association between HRV and higher exacerbation severity on presentation (regression = .016) and between the presence of any pathogen and emergency department treatment failure (odds ratio [OR] = 1.57; 95% CI 1.04% to 2.37%). High-quality evidence for effect on morbidity or health care use is lacking.

CONCLUSIONS

Further research on the role of pathogen-treatment interaction and outcomes is required to inform the need for point-of-care, real-time testing for pathogens. Studies with a sufficiently large sample size that address selection bias, correctly adjust for confounding, and rigorously report core patient-centred outcomes are necessary to improve knowledge.